Eli Lilly and Company (LLY)
| Market Cap | 687.38B |
| Revenue (ttm) | 49.00B |
| Net Income (ttm) | 11.11B |
| Shares Out | 897.74M |
| EPS (ttm) | 12.29 |
| PE Ratio | 62.30 |
| Forward PE | 30.68 |
| Dividend | $6.00 (0.78%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 3,638,629 |
| Open | 769.50 |
| Previous Close | 765.84 |
| Day's Range | 753.05 - 770.00 |
| 52-Week Range | 677.09 - 972.53 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 1,014.22 (+32.46%) |
| Earnings Date | May 1, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $1,014.22, which is an increase of 32.46% from the latest price.
News
Rare Outflow Signals Hit Eli Lilly Shares
“Buy low, sell high” is a common investing mantra. It's easy to understand, but often hard to execute because emotion gets in the way.
Lilly's Jake Van Naarden: Lilly's success with GLP-1's allows us to reinvest in oncology
CNBC's Angelica Peebles sits down with Lilly's Head of Oncology, Jake Van Naarden, to discuss what's next in Lilly's oncology pipeline and what Lilly is changing about its clinical trials to make them...
Welldoc Works with Lilly to Launch a New Personalized Health & Medicine Platform for Those Prescribed Lilly's Incretin Therapies
COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a leader in AI-powered digital health innovation, today announced it will power the newly launched Lilly Health™ Personalized Health & Medicine Platform* (Lil...
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million in pote...
Top 50 High-Quality Dividend Stocks For June 2025
I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities. In this turbulent year, my investable universe ...
LLY Stock Too Cheap At $750?
Question: Why would you pay 81 times earnings for AbbVie stock when you can buy LLY for a similar valuation of 76 times earnings? You wouldn't, especially when you consider three simple facts:
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly exe...
Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
Both Vertex and Eli Lilly are entering the non-opioid pain management market, targeting the promising $20B+ opportunity. Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pai...
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) de...
Eli Lilly Rises 1.5% After Key Trading Signal
TradePulse Alert Confirms Early Up Move in LLY
5 Alpha Generating Monsters
Any stock can generate alpha, but doing it consistently is rare. These 5 stocks have delivered alpha for 4 out of the last 5 years. Valuation is important, so I screen for it and eliminate overpriced ...
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
INDIANAPOLIS , May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatr...
Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives
Eli Lilly And Co LLY on Tuesday agreed to acquire SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal h...
Eli Lilly to acquire privately held SiteOne
Eli Lilly will acquire privately held SiteOne Therapeutics, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain drug.
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS , May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc...
Weight-loss drugs like Ozempic and Wegovy continue to be in high demand—and expensive. Are prices likely to come down soon?
The supply of GLP-1 drugs has been increasing, but they're still expensive for most patients. Here are answers to some questions consumers have.
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
INDIANAPOLIS , May 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD...
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna's Evernorth unit said a new coverage deal with Eli Lilly and Novo Nordisk will bring lower copays for insured patients The company hopes the new discount, which caps monthly out-of-pocket costs ...
Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease
The authorization in Australia is for adult patients who are Apolipoprotein E- ε 4 heterozygotes or non-carriers INDIANAPOLIS , May 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced...
Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound
The company delivered 45% revenue growth in Q1 2025, driven by ZEPBOUND and MOUNJARO's strong performance in the obesity and diabetes markets. ZEPBOUND outperformed Novo Nordisk's WEGOVY in terms of w...
Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in
The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the Danish pharmaceutical giant announced it would replace its long-serving chie...
3 Stocks That Will Profit From Trump's Drug Price Cut
On May 12, President Donald Trump followed through on a campaign promise by signing an Executive Order (EO) mandating that pharmaceutical companies lower their prescription drug prices in the US to th...
Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript
Eli Lilly and Company (NYSE:LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participants...
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.